Figure 3.

Estimated vaccine efficacy in preventing severe illness in those with SARS-CoV-2. Severe coronavirus disease 2019 outcomes associated with second-dose vaccination, unadjusted and in the adjusted model, and the adjusted effectiveness in subgroups are shown. N is the number of SARS-CoV-2 infections at least 10 days after the second vaccine dose in each group. Efficacy is calculated as 1 – odds ratio. 95% CI, 95% confidence interval. ^aWithin 14 days of positive PCR. ^bWithin 28 days of positive PCR.